Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
about
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy receivedAssociation of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancerThe Potential Role of Hedgehog Signaling in the Luminal/Basal Phenotype of Breast Epithelia and in Breast Cancer Invasion and MetastasisTowards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis.Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.BCL2 inhibits cell adhesion, spreading, and motility by enhancing actin polymerization.BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.Significance of immunohistochemistry in breast cancerOverexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis.Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.BCL2 interaction with actin in vitro may inhibit cell motility by enhancing actin polymerization.Prognostic value of mitotic index and Bcl2 expression in male breast cancer.BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasionNew castanospermine glycoside analogues inhibit breast cancer cell proliferation and induce apoptosis without affecting normal cellsPrognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysisReduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells.The impact of matrix metalloproteinase 2 on prognosis and clinicopathology of breast cancer patients: a systematic meta-analysis.Lack of association between bcl-2 expression and prognosis of osteosarcoma: a meta-analysisSensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic reviewComprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteriaPrognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis.Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regressionDetection methods predict differences in biology and survival in breast cancer patients.Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterpartsDoes the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients.Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.Hedgehog signalling in breast cancer.Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Neem leaf extract inhibits mammary carcinogenesis by altering cell proliferation, apoptosis, and angiogenesis.An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors.PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.Prognostic Influence of BCL2 on Molecular Subtypes of Breast CancerMeta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.
P2860
Q24610409-3787296A-A8CE-4FCF-A9A2-7AA8BEC70130Q24653339-CBD40414-F0F7-43B2-88FE-9D132E4B93E0Q26782727-8A2651F0-6335-46BE-9BE9-73FAB33D270DQ30445250-C14DC516-73E8-40F1-BCB5-9CBCC2B2920AQ33762003-13FDCB4D-6CAC-46FA-B0A7-F618BEDA6498Q33766199-3E2C8092-ABD3-4390-A5E7-D20C9DEA2F63Q33860466-B39E938F-8016-4025-9A57-B105BDB59D44Q33870504-CAB1C0B6-44A7-4639-8C44-9862B6745A24Q34023682-2C955601-8743-4280-BFEB-D4830EC879D5Q34082775-839640F4-0EE1-4437-9EE6-E019DEDD48CAQ34198351-2D3189A6-A856-47E3-AF59-E43565049847Q34491903-F1E94807-9B7E-4A4D-8AE6-47ECA0104392Q34570293-1D8CA5AD-3DF9-490D-AD50-7205422F2A98Q34661870-318BCE64-4670-47C9-A43C-FDC9B089CA15Q35006788-DEA6C9F5-AD5C-4C9A-A164-B5398AE3220AQ35016962-84463D80-B0DF-4281-8559-EF70D1EEB238Q35106431-0836ECE2-6A90-4A86-BB6D-2AC46226D78EQ35212637-0D19815F-1BE4-48BE-8931-7450375FC42BQ35225035-3EA7045A-5E54-4ED9-B211-5D6E5B66745EQ35756386-95FB5378-AA32-4EFF-9ECA-95B9B6F85E68Q35779325-09D28DC2-8748-49FA-BCC5-6E46E57D8B8EQ35809680-4E915C53-23B3-44C9-A739-7C96D09BC002Q35851986-7918E86B-BCF2-4FC3-B8D5-979258153EE3Q36075768-B0F7B4B1-608C-44C2-BE00-0575734E2084Q36182244-5783F3B7-73F0-4301-B802-DD26A9C2B4ECQ36355467-CD7911A1-EC29-46D0-9DED-79E9B8BE30EEQ36521102-210DCDA2-1EB8-4B2D-99F2-FF56ABC88E75Q36746712-D3A0A6E8-DF05-448F-B5B2-5078EFC5F770Q36966828-01056E07-347D-4014-A6D2-36CF4E84FF7FQ37052173-876AFE50-F046-47D8-BD29-51C98FE18356Q37096479-26F25A9C-0696-4E3C-A7C3-E1067A0155ADQ37214195-23A6F7C7-F3D1-41F5-AB4A-65FF00087036Q37356185-74E323D0-919B-4A19-975D-8EA49070B0BAQ37401549-73BA13D3-D65A-40CC-B961-0BA1571F4F9AQ37565213-B542BC65-7257-4DE0-A2DF-D36B798F63F4Q37610084-638A7605-87D9-45B4-8848-FCB174CE5E36Q37691657-018EA10F-AEE1-4B7A-8C94-CDE6625ADFE3Q37702222-E268B91C-DF1E-4CA5-A2DB-5031DECEE959Q37735963-10873388-6928-4BA6-BDE5-564F3CEB7840Q37859255-0E0369E9-BC26-48BB-99C8-7EB918392025
P2860
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@ast
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@en
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@nl
type
label
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@ast
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@en
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@nl
prefLabel
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@ast
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@en
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@nl
P2860
P31
P921
P356
P1433
P1476
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
@en
P2093
Grace M Callagy
Mark J Webber
P2860
P2888
P356
10.1186/1471-2407-8-153
P407
P5008
P577
2008-05-29T00:00:00Z
P5875
P6179
1037036730